Learn more about WIPO Re:Search members by viewing their detailed profiles.
WIPO Re:Search Resource Platform terms and conditions of use
Re:Search Institution Members
Export data
Choose one option to export the data.
PPT
141 Results for Members
Members
Monash University hosts many of Australia’s premier research centers and institutions. Research at Monash...
The National University of Singapore (NUS) was founded in 1905 as a medical college. The Duke-NUS Medical...
Based on a tradition of global engagement, and creative approaches to education and research, Northeastern...
With its 18 interdisciplinary centers, cross-sector collaborative research is commonplace at Stanford. This...
Established in 1943, Swiss TPH conducts research on malaria, HIV, tuberculosis and other infectious diseases...
Researchers at UBC undertake a variety of research and development activities related to diseases of poverty,...
156 Results for Collaborations
Collaborations
Drs. Meyers and Wildman were interested in the potential of PDE inhibitors to target a specific protein of interest in Mycobacterium tuberculosis (MTb). BVGH connected them with Dr. Pollastri, who had synthesized a set of PDE inhibitors as potential new drugs for HAT. Dr. Pollastri shared the structures of his compounds with Drs. Meyers and Wildman, who performed virtual docking studies to predict whether the inhibitors might have activity against MTb.
AstraZeneca scientists were interested in screening natural products for activity against M. tuberculosis. BVGH connected AstraZeneca with Dr. Quinn, who provided AstraZeneca with the GRIDD Nature Bank Fraction Library for their screening assays.
Cathepsins have been identified as potential drug targets across a range of infectious organisms. Drs. Caffrey, McKerrow, and Dr. Rosenthal were interested in screening cathepsin inhibitors against a selection of parasitic organisms. BVGH connected them with AstraZeneca, which provided cysteine protease inhibitors for screening against both human and parasitic enzyme targets.
Buruli ulcer, caused by Mycobacterium ulcerans, is a neglected tropical disease that, if left untreated, can cause debilitating skin ulcers and destruction of soft tissue. Current treatment involves eight weeks of antibiotics, a difficult course to implement in resource-limited settings. Drs. Pluschke and Scherr were interested in screening compounds against Buruli ulcer that had showed promise in screens against M. tuberculosis, as M. ulcerans is closely related to M. tuberculosis. BVGH facilitated a collaboration with AstraZeneca, which shared 100 anti-tuberculosis compounds (including one in clinical trials) for the Swiss TPH investigators to screen in their Buruli ulcer assay. While a number of potent antitubercular agents were only weakly active or inactive against M. ulcerans, five compounds showed high activity, making screening of focused antitubercular libraries a good starting point for lead generation against M. ulcerans.
Dr. Podust, an x-ray crystallographer, had been working on structure-based drug design for Chagas disease, and was interested in the potential of Cyp51 inhibitors. BVGH connected Dr. Podust with AstraZeneca, which shared 905 Cyp51 inhibitors. Dr. Podust’s collaborators, Drs. McKerrow and Siqueira-Neto, screened the compounds in high-throughput and cell-based assays against T. cruzi.
Key Personnel: Michael Pollastri (Northeastern University), Jean-Robert Ioset (DNDi), Byron Arana (DNDi), Marcel Kaiser (Swiss TPH). Dr. Pollastri had identified promising compounds in a screen against Leishmania major (the pathogen that causes cutaneous leishmaniasis). To support drug development efforts against additional neglected diseases, Dr. Pollastri shared his screening data with Drs. Arana and Ioset. With this data, Drs. Arana and Ioset connected with Dr. Kaiser, who screened the compounds for activity against Trypanosoma cruzi, T. brucei, L. donovani, and Plasmodium falciparum. Dr. Kaiser further conducted counter screens to assess cellular cytotoxicity.
172 Results for Assets
Assets
A A suite of freely-available software tools for electronic disease surveillance in resource-limited settings from Johns Hopkins applied physics laboratory and the Armed Forces Health Surveillance Center (AFHSB). Public health surveillance is undergoing a revolution driven by advances in the field of information technology. Many countries have experienced vast improvements in the collection, ingestion, analysis, visualization, and dissemination of public health data. Resource-limited countries have lagged behind due to challenges in information technology infrastructure, public health resources, and the costs of proprietary software. The Suite for Automated Global Electronic bioSurveillance (SAGES) is a collection of modular, flexible, freely-available software tools for electronic disease surveillance in resource-limited settings. One or more SAGES tools may be used in concert with existing surveillance applications or the SAGES tools may be used en masse for an end-to-end biosurveillance capability. This flexibility allows for the development of an inexpensive, customized, and sustainable disease surveillance system. The ability to rapidly assess anomalous disease activity may lead to more efficient use of limited resources and better compliance with World Health Organization International Health Regulations. reference PLoS ONE 6(5): e19750.doi:10.1371/journal.pone.0019750
The efficient and affordable regioselective methods for the synthesis of vinyl sulfones. These methods allow for the study of structure-activity relationships of various analogs of 4-methyl-N- S -1-oxo-3-phenyl-1- S,E -5-phenyl-1- phenylsulfonyl pent-1-en-3-yl amino propan-2-yl piperazine-1-carboxamide K777 . Vinyl sulfones obtained from the methods described may be useful in organic synthesis of sulfur-containing compounds. Compounds prepared by the methods described may be useful for the treatment of cancers and infectious diseases including Chagas’ disease, as well as other diseases caused by an infection of a parasite of the genus Trypanosoma. Compounds prepared by the methods described may also be useful for treatments requiring the inhibition of polo-like kinase 1 PLK1 , MAP kinases and cysteine proteases.
Mycobacteria are a significant cause of morbidity and mortality, particularly among immunocompromised or elderly individuals and in countries with limited medical resources. Ninety-five percent of human infections are caused by seven species: Mycobacterium tuberculosis, M. avium (also known as the mycobacterium avium complex or M. avium-intracellulare), M. leprae, M. kansasii, M. fortuitum, M. chelonae, and M. absecessus. The most common mycobacterial infections in the United States are pulmonary infections by M. tuberculosis or M. avium. Such mycobacterial infections have been of increasing concern over the past decade, particularly in light of the increasing incidence of multi-drug resistant strains.
We provide collaborative research capability in hit-to-lead and lead optimization medicinal chemistry for protozoan diseases (primarily) and other NTDs. We have established internal programs, and are looking for collaborators who wish to share early chemistry data to initiate optimization programs.
Professors Thomas Dick and Nick Paton at the National University of Singapore have the capacity to develop anti-tuberculosis compounds all the way from target discovery to proof of concept, preclinical and clinical development. They are interested in exploring potential collaborations around chemically validated targets. They also have capability for target identification for compounds with interesting whole cell activity. They are also interested in speaking with researchers with advanced compounds, optimized leads and can support preclinical development if there is mutual interest, including PK, PD, rat tox and formulation. Compounds modulating host response will be considered only if they are at the stage of entering clinical trials.
Optical diagnostic: see summary at http://www.wipo.int/research/en/data/mcgill_07116_wiseman.pdf. This invention proposed a unique system for the detection of malaria which would be based on the sensitive detection of the infection via laser excited third harmonic generation THG emission generated from hemozoin present in red blood cells containing malaria parasites.